Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06539468 · ClinicalTrials.gov registry record · NA
Active Surveillance for the Treatment of Low-Risk Basal Cell Carcinoma in Elderly Patients
A NA study of Skin Basal Cell Carcinoma, sponsored by University of Michigan Rogel Cancer Center.
- Recruiting
- Registry status
- NA
- Development phase
- 200
- Enrollment target
- 1
- Study location
NCT06539468 is a NA study of Skin Basal Cell Carcinoma that is actively recruiting participants, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 200 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06539468, a NA study of Skin Basal Cell Carcinoma, is actively recruiting participants, sponsored by University of Michigan Rogel Cancer Center.
- RECRUITING
- Registry status
- NA
- Development phase
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
This clinical trial evaluates whether active surveillance (AS) is a safe and comfortable alternative to standard of care (SOC) treatment for elderly patients with low-risk basal cell carcinoma (LR-BCC). Basal cell carcinoma is a type of slow-growing skin cancer that has a very low risk of spreading inside the body (metastasis) or death. Basal cell skin cancers that are smaller across than a nickel in size and located on the trunk or limbs are particularly low risk to overall health. Active surveillance - watching and not treating unless the cancer worsens - has been shown to be a generally safe way to manage LR-BCC. Despite this, many doctors do not feel comfortable discussing this option with patients due to a lack of studies comparing it to standard of care treatment. Standard of care treatment for LR-BCC can include "scrape and burn" (electrodesiccation and curettage), surgical resection, Mohs surgery, and other approaches. These treatments can carry risks like post-operative bleeding and wound infection, and they do not always improve tumor-related quality of life. Active surveillance may be a safe and comfortable alternative to SOC treatment for elderly patients with LR-BCC.
Conditions Studied
Interventions
- OTHER Survey Administration
- OTHER Best Practice
- OTHER Patient Observation
- OTHER Educational Activity
Study Locations (1)
Michigan
- University of Michigan Comprehensive Cancer Center - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2024-10-08 |
| Est. Completion | 2025-12-28 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06539468
The ClinicalTrials.gov registry entry for NCT06539468 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan Rogel Cancer Center, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Skin Basal Cell Carcinoma appearing as the primary indexed condition, and to 4 interventions - of which Survey Administration is the first listed.
NCT06539468 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.
Frequently Asked Questions
What is clinical trial NCT06539468 about?
NCT06539468 is a clinical study titled "Active Surveillance for the Treatment of Low-Risk Basal Cell Carcinoma in Elderly Patients". This clinical trial evaluates whether active surveillance (AS) is a safe and comfortable alternative to standard of care (SOC) treatment for elderly patients with low-risk basal cell carcinoma (LR-BCC). Basal cell carcinoma is a type of slow-growing skin cancer that has a very low risk of spreading ...
What is the current status of trial NCT06539468?
This trial is currently recruiting. It is a NA study. The enrollment target is 200 participants. The study started on 2024-10-08. Estimated completion is 2025-12-28.
What conditions does trial NCT06539468 study?
This clinical trial studies the following conditions: Skin Basal Cell Carcinoma.
What interventions are being tested in trial NCT06539468?
The interventions under investigation include: Survey Administration (OTHER), Best Practice (OTHER), Patient Observation (OTHER), Educational Activity (OTHER).
Who is sponsoring clinical trial NCT06539468?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06539468 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Skin Basal Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Intratumoral Injection of Standard Universal Donor Expanded Natural Killer Cells and TGF-beta Imprinted Natural Killer Cells for the Treatment of Skin Squamous Cell Carcinoma and Basal Cell Carcinoma
RECRUITING · Early Phase 1
-
Topical Remetinostat in Treating Patient With Cutaneous Basal Cell Cancer
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.